Cargando…

Hypoxia Selects Bortezomib-Resistant Stem Cells of Chronic Myeloid Leukemia

We previously demonstrated that severe hypoxia inhibits growth of Chronic Myeloid Leukemia (CML) cells and selects stem cells where BCR/Abl(protein) is suppressed, although mRNA is not, so that hypoxia-selected stem cells, while remaining leukemic, are independent of BCR/Abl signaling and thereby re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanturli, Michele, Giuntoli, Serena, Barbetti, Valentina, Rovida, Elisabetta, Dello Sbarba, Persio
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037943/ https://www.ncbi.nlm.nih.gov/pubmed/21347297 http://dx.doi.org/10.1371/journal.pone.0017008

Ejemplares similares

Chronic Myeloid Leukemia and Hepatoblastoma: Two Cancer Models to Link Metabolism to Stem Cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2016)

One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a “hypoxic” environment
por: Rovida, Elisabetta, et al.
Publicado: (2014)

AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia
por: Barbetti, V, et al.
Publicado: (2013)

The Colony-Stimulating Factor-1 (CSF-1) Receptor Sustains ERK1/2 Activation and Proliferation in Breast Cancer Cell Lines
por: Morandi, Andrea, et al.
Publicado: (2011)

Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells
por: Barbetti, Valentina, et al.
Publicado: (2013)

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features
por: Tusa, Ignazia, et al.
Publicado: (2020)

Sensitivity to imatinib of KCL22 chronic myeloid leukemia cell survival/growth and stem cell potential under glucose shortage
por: Bono, Silvia, et al.
Publicado: (2018)

The Culture-Repopulating Ability Assays and Incubation in Low Oxygen: A Simple Way to Test Drugs on Leukaemia Stem or Progenitor Cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2013)

Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells
por: Tusa, Ignazia, et al.
Publicado: (2018)

The Leukemic Stem Cell Niche: Adaptation to “Hypoxia” versus Oncogene Addiction
por: Cheloni, Giulia, et al.
Publicado: (2017)

Lactate Maintains BCR/Abl Expression and Signaling in Chronic Myeloid Leukemia Cells Under Nutrient Restriction
por: Silvano, Angela, et al.
Publicado: (2022)

Correction to Barbetti V, et al. Epigenetics Volume 8, Issue 2; pp. 210–9
por: Barbetti, Valentina, et al.
Publicado: (2013)

Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction
por: Bono, Silvia, et al.
Publicado: (2016)

Glutamine Availability Controls BCR/Abl Protein Expression and Functional Phenotype of Chronic Myeloid Leukemia Cells Endowed with Stem/Progenitor Cell Potential
por: Poteti, Martina, et al.
Publicado: (2021)

Beyond Kinase Activity: ERK5 Nucleo-Cytoplasmic Shuttling as a Novel Target for Anticancer Therapy
por: Tubita, Alessandro, et al.
Publicado: (2020)

Low-dose methotrexate enhances cycling of highly anaplastic cancer cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2016)

Cancer stemness and progression: mitochondria on the stage
por: Chiarugi, Paola, et al.
Publicado: (2015)

Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence
por: Ianniciello, Angela, et al.
Publicado: (2017)

Hypoxia-resistant profile implies vulnerability of cancer stem cells to physiological agents, which suggests new therapeutic targets
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2014)

Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures
por: Masala, Erico, et al.
Publicado: (2018)

The complex metabolic network gearing the G(1)/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents
por: Stivarou, Theodora, et al.
Publicado: (2015)

The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy
por: Rovida, Elisabetta, et al.
Publicado: (2014)

Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells
por: Hallal, Rawan, et al.
Publicado: (2020)

The Hedgehog-GLI Pathway Regulates MEK5-ERK5 Expression and Activation in Melanoma Cells
por: Tusa, Ignazia, et al.
Publicado: (2021)

mTORC2 Is Activated under Hypoxia and Could Support Chronic Myeloid Leukemia Stem Cells
por: Panuzzo, Cristina, et al.
Publicado: (2023)

Chronic myeloid leukemia stem cells
por: Houshmand, Mohammad, et al.
Publicado: (2019)

Bortezomib has little ex vivo activity in chronic myeloid leukemia: individual tumor response testing comparative study in acute and chronic myeloid leukemia
por: Styczyński, Jan, et al.
Publicado: (2012)

Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
por: Tubita, Alessandro, et al.
Publicado: (2022)

A Case of Multiple Myeloma with Metachronous Chronic Myeloid Leukemia Treated Successfully with Bortezomib, Dexamethasone, and Dasatinib
por: Alsidawi, Samer, et al.
Publicado: (2014)

Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis
por: Yang, Xiaojuan, et al.
Publicado: (2016)

Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells
por: Barbetti, V, et al.
Publicado: (2014)

Leukemia stem cells: the root of chronic myeloid leukemia
por: Zhou, Hong, et al.
Publicado: (2015)

Bortezomib suppresses self‐renewal and leukemogenesis of leukemia stem cell by NF‐ĸB‐dependent inhibition of CDK6 in MLL‐rearranged myeloid leukemia
por: Zhou, Bin, et al.
Publicado: (2021)

Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells
por: Houshmand, Mohammad, et al.
Publicado: (2021)

Chronic Myeloid Leukemia Stem Cell Biology
por: Crews, Leslie A., et al.
Publicado: (2012)

Stem Cell Biomarkers in Chronic Myeloid Leukemia
por: Jiang, Xiaoyan, et al.
Publicado: (2008)

Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
por: Bista, Ranjan, et al.
Publicado: (2017)

Synthetic biology of hypoxia
por: Licausi, Francesco, et al.
Publicado: (2020)

Bosutinib in chronic myeloid leukemia: patient selection and perspectives
por: Isfort, Susanne, et al.
Publicado: (2018)

Molecular signatures of chronic myeloid leukemia stem cells
por: Chen, Yaoyu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fanpkg36bdl3grtq6mv3vko891